Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen

Trial Profile

A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FRM 6308 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 09 Oct 2014 Planned primary completion date changed from 1 Feb 2015 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 09 Oct 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Feb 2014 Planned End Date changed from 1 Nov 2014 to 1 Feb 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top